Out in npj Journals Breast: real-world🌎 study from a large cohort (n=5910) of pts with HR+/HER2- #breastcancer
🔸ESR1 alterations were⬆️in secondary vs. primary endocrine resistance
🔹TP53 alterations were⬆️ in primary vs. secondary resistance
OncoAlert
nature.com/articles/s4152…

Congrats!

Thanks for your support in improving care for all patients with #cancer ASCO Conquer Cancer, the ASCO Foundation

We miss you! But you were on my slides! Ana I. Velázquez Mañana, MD MSc (she/her/ella) Narjust Florez, MD, FASCO Dr. Estela Rodriguez

Thanks, Toni Choueiri, MD it’s an honor to serve

Thanks for your support! I’m honored to serve improve the care for p#patients with cancer ASCO

Agree!! I called Ana I. Velázquez Mañana, MD MSc (she/her/ella) Narjust Florez, MD, FASCO of them to see if they were coming

One of our favorite talks to put together is the Patient Advocate Talk, and we are so thrilled to have TerriConneran KRASKickers - coming up next! #TTLC24 IASLC
Lecia Sequist, MD, MPH Joel W. Neal, MD, PhD Karen Kelly

🚨 #LatinoCancer2924 Make sure to attend Idalid "Ivy" Franco MD MPH ‘s talk at 10am on improving recruitment and retention of a #diverse #workforce

#LatinasInMedicine #LatinosInOncology #FlorezLab Salud America! Fernando Diaz, MD

🎉Congratulations to the newly appointed @asco FASCO recipients - many collaborators and oncologists I admire for their work on this list.
Narjust Florez, MD, FASCO Stephanie Graff, MD, FACP, FASCO Dr. Luis E. Raez Gladys Rodriguez,MD, FASCO Raymond Osarogiagbon, MBBS, FACP

Can’t be in better company! Stephanie Graff, MD, FACP, FASCO

Thanks for your support! Stephanie Graff, MD, FACP, FASCO

ASCO Congratulations to all my fellow inductees—especially friends & collaborators Narjust Florez, MD, FASCO Gladys Rodriguez,MD, FASCO Shaalan Beg MD MBA FASCO Alex Spira, M.D. #FASCO

Thanks! I’m honor

Thanks for the opportunity to serve the members of ASCO, and more important to be part of efforts to improve the care of patients with cancer ASCO. Thanks to Skip Burris for his support

Im honor to help out Latino Patient Advocates learn about Clinical Trials

So sooty I missed dinner, but honor to talked about clinical trials and why we should participate!

“Among pts with RCB-0/1, over half (21/38 [55.3%]) of all events were CNS recurrences, with 13/22 (59.1%) in the pembro group and 8/16 (50.0%) in the placebo group.”

Brain Mets account for 60% of events in RCB0/1 pts on Keynote 522. We would need to predict to prevent. #bcsm

I’m honor to be an invited speaker, see you all tomorrow!

Elevating Equity for Latinas in Cancer Research: A Conversation With Dr. Gladys Rodriguez | ASCO Connection. Thanks to ⁦ASCO⁩ for amplifying my voice! ⁦ASCOPres⁩ #LatinaWWCCYIA ⁦Narjust Florez, MD, FASCO⁩ connection.asco.org/magazine/featu…